Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson Sells 248,645 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Gilead Sciences Stock Down 1.6 %

Shares of NASDAQ GILD opened at $92.49 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The firm has a fifty day moving average of $88.63 and a 200-day moving average of $78.20. The stock has a market capitalization of $115.27 billion, a PE ratio of 1,027.67, a P/E/G ratio of 2.92 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the previous year, the company earned $2.29 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, analysts anticipate that Gilead Sciences, Inc. will post 4.37 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.33%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Institutional Trading of Gilead Sciences

A number of institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. boosted its position in Gilead Sciences by 22.8% during the 3rd quarter. Franklin Resources Inc. now owns 2,241,354 shares of the biopharmaceutical company’s stock worth $190,611,000 after purchasing an additional 416,379 shares during the period. Tri Ri Asset Management Corp purchased a new stake in Gilead Sciences during the 3rd quarter worth $3,380,000. Synovus Financial Corp lifted its holdings in Gilead Sciences by 99.6% in the 3rd quarter. Synovus Financial Corp now owns 37,265 shares of the biopharmaceutical company’s stock worth $3,124,000 after buying an additional 18,592 shares in the last quarter. Tidal Investments LLC lifted its holdings in Gilead Sciences by 9.9% in the 3rd quarter. Tidal Investments LLC now owns 111,464 shares of the biopharmaceutical company’s stock worth $9,345,000 after buying an additional 10,078 shares in the last quarter. Finally, Optimist Retirement Group LLC lifted its holdings in Gilead Sciences by 5.4% in the 3rd quarter. Optimist Retirement Group LLC now owns 27,234 shares of the biopharmaceutical company’s stock worth $2,283,000 after buying an additional 1,391 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on GILD shares. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald lifted their price objective on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Twelve research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $95.41.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.